• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

细胞外基质代谢生物标志物(MMP-9 和 TIMP-1)与卒中、心肌梗死和特定原因死亡率的关系:队列研究。

Biomarkers of extracellular matrix metabolism (MMP-9 and TIMP-1) and risk of stroke, myocardial infarction, and cause-specific mortality: cohort study.

机构信息

Department of Medical Sciences, Uppsala University, Uppsala, Sweden.

出版信息

PLoS One. 2011 Jan 19;6(1):e16185. doi: 10.1371/journal.pone.0016185.

DOI:10.1371/journal.pone.0016185
PMID:21283828
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3023803/
Abstract

OBJECTIVE

Turnover of the extracellular matrix in all solid organs is governed mainly by a balance between the degrading matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs). An altered extracellular matrix metabolism has been implicated in a variety of diseases. We investigated relations of serum levels of MMP-9 and TIMP-1 to mortality risk from an etiological perspective.

DESIGN

The prospective Uppsala Longitudinal Study of Adult Men (ULSAM) cohort, followed from 1991-1995 for up to 18.1 years. A random population-based sample of 1,082 71-year-old men, no loss to follow-up. Endpoints were all-cause (n = 628), cardiovascular (n = 230), non-cardiovascular (n = 398) and cancer mortality (n = 178), and fatal or non-fatal myocardial infarction (n = 138) or stroke (n = 163).

RESULTS

Serum MMP-9 and TIMP-1 levels were associated with risk of all-cause mortality (Cox proportional hazard ratio [HR] per standard deviation 1.10, 95% confidence interval [CI] 1.03-1.19; and 1.11, 1.02-1.20; respectively). TIMP-1 levels were mainly related to risks of cardiovascular mortality and stroke (HR per standard deviation 1.22, 95% CI 1.09-1.37; and 1.18, 1.04-1.35; respectively). All relations except those of TIMP-1 to stroke risk were attenuated by adjustment for cardiovascular disease risk factors. Relations in a subsample without cardiovascular disease or cancer were similar to those in the total sample.

CONCLUSION

In this community-based cohort of elderly men, serum MMP-9 and TIMP-1 levels were related to mortality risk. An altered extracellular matrix metabolism may be involved in several detrimental pathways, and circulating MMP-9 or TIMP-1 levels may be relevant markers thereof.

摘要

目的

所有实体器官细胞外基质的周转率主要由降解基质金属蛋白酶(MMPs)与其组织抑制剂(TIMPs)之间的平衡来调控。细胞外基质代谢的改变与多种疾病有关。我们从病因学的角度研究了血清 MMP-9 和 TIMP-1 水平与死亡率风险之间的关系。

设计

前瞻性乌普萨拉男性成人纵向研究(ULSAM)队列,从 1991-1995 年开始随访,最长时间为 18.1 年。一个随机的基于人群的 1082 名 71 岁男性样本,无随访丢失。终点是全因(n=628)、心血管(n=230)、非心血管(n=398)和癌症死亡率(n=178),以及致命或非致命性心肌梗死(n=138)或中风(n=163)。

结果

血清 MMP-9 和 TIMP-1 水平与全因死亡率风险相关(每标准差 Cox 比例风险比 [HR]为 1.10,95%置信区间 [CI]为 1.03-1.19;和 1.11,1.02-1.20)。TIMP-1 水平主要与心血管死亡率和中风风险相关(每标准差 HR 为 1.22,95%CI 为 1.09-1.37;和 1.18,1.04-1.35)。除 TIMP-1 与中风风险的关系外,所有这些关系在调整心血管疾病危险因素后均减弱。在没有心血管疾病或癌症的亚样本中,结果与总样本相似。

结论

在这个基于社区的老年男性队列中,血清 MMP-9 和 TIMP-1 水平与死亡率风险相关。细胞外基质代谢的改变可能涉及到几种有害途径,而循环 MMP-9 或 TIMP-1 水平可能是其相关标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18d1/3023803/055a4009c75f/pone.0016185.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18d1/3023803/703cbf80096e/pone.0016185.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18d1/3023803/055a4009c75f/pone.0016185.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18d1/3023803/703cbf80096e/pone.0016185.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18d1/3023803/055a4009c75f/pone.0016185.g002.jpg

相似文献

1
Biomarkers of extracellular matrix metabolism (MMP-9 and TIMP-1) and risk of stroke, myocardial infarction, and cause-specific mortality: cohort study.细胞外基质代谢生物标志物(MMP-9 和 TIMP-1)与卒中、心肌梗死和特定原因死亡率的关系:队列研究。
PLoS One. 2011 Jan 19;6(1):e16185. doi: 10.1371/journal.pone.0016185.
2
Relations of serum MMP-9 and TIMP-1 levels to left ventricular measures and cardiovascular risk factors: a population-based study.血清基质金属蛋白酶-9和金属蛋白酶组织抑制因子-1水平与左心室指标及心血管危险因素的关系:一项基于人群的研究。
Eur J Cardiovasc Prev Rehabil. 2009 Jun;16(3):297-303. doi: 10.1097/HJR.0b013e3283213108.
3
Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).基质金属蛋白酶-9和金属蛋白酶组织抑制因子-1在高血压中的作用及其与心血管风险和治疗的关系:盎格鲁-斯堪的纳维亚心脏结局试验(ASCOT)的一项子研究
Am J Hypertens. 2004 Sep;17(9):764-9. doi: 10.1016/j.amjhyper.2004.05.019.
4
Serum tissue inhibitor of matrix metalloproteinase-1 levels are associated with mortality in patients with malignant middle cerebral artery infarction.血清基质金属蛋白酶-1组织抑制剂水平与恶性大脑中动脉梗死患者的死亡率相关。
BMC Neurol. 2015 Jul 11;15:111. doi: 10.1186/s12883-015-0364-7.
5
Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction.金属蛋白酶组织抑制剂-1(TIMP-1)是全因死亡率、心脏死亡率和心肌梗死的独立预测指标。
Am Heart J. 2006 May;151(5):1101.e1-8. doi: 10.1016/j.ahj.2006.02.029.
6
Serum tissue-degrading proteinases and incident cardiovascular disease events.血清组织降解蛋白酶与心血管疾病事件的发生。
Eur J Prev Cardiol. 2014 Jul;21(7):806-12. doi: 10.1177/2047487312465524. Epub 2012 Oct 18.
7
Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis.基质金属蛋白酶-9、-10 和基质金属蛋白酶组织抑制剂-1 的血液水平作为脓毒症严重程度和死亡率的生物标志物。
Crit Care. 2009;13(5):R158. doi: 10.1186/cc8115. Epub 2009 Oct 2.
8
Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study.血浆基质金属蛋白酶与1型糖尿病患者心血管疾病的发生及全因死亡率相关:一项12年随访研究
Cardiovasc Diabetol. 2017 Apr 26;16(1):55. doi: 10.1186/s12933-017-0539-1.
9
Matrix metalloproteinases and their inhibitors in different acute stroke subtypes.不同急性卒中亚型中的基质金属蛋白酶及其抑制剂
Clin Chem Lab Med. 2006;44(4):428-34. doi: 10.1515/CCLM.2006.079.
10
Circulating levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with incisional hernia.切口疝患者中基质金属蛋白酶和金属蛋白酶组织抑制剂的循环水平。
Wound Repair Regen. 2013 Sep-Oct;21(5):661-6. doi: 10.1111/wrr.12071. Epub 2013 Aug 8.

引用本文的文献

1
The relationship between tissue inhibitor of metalloproteinases-1 and KCNJ5 mutation in aldosterone-producing adenoma patients.醛固酮瘤患者中金属蛋白酶组织抑制剂-1与KCNJ5突变之间的关系
Hypertens Res. 2025 Feb;48(2):563-573. doi: 10.1038/s41440-024-02030-w. Epub 2024 Dec 17.
2
The TIMP protein family: diverse roles in pathophysiology.TIMP 蛋白家族:在病理生理学中的多种作用。
Am J Physiol Cell Physiol. 2024 Mar 1;326(3):C917-C934. doi: 10.1152/ajpcell.00699.2023. Epub 2024 Jan 29.
3
A functional -1562C>T polymorphism, MMP-9 serum levels and nephrolithiasis risk in a southern Chinese population.

本文引用的文献

1
Relations of biomarkers of extracellular matrix remodeling to incident cardiovascular events and mortality.细胞外基质重塑生物标志物与心血管事件和死亡率的关系。
Arterioscler Thromb Vasc Biol. 2010 Nov;30(11):2283-8. doi: 10.1161/ATVBAHA.110.208462. Epub 2010 Aug 26.
2
Prospective study of matrix metalloproteinase-9 and risk of myocardial infarction and stroke in older men and women.前瞻性研究基质金属蛋白酶-9与老年男性和女性心肌梗死和中风风险的关系。
Atherosclerosis. 2010 Feb;208(2):557-63. doi: 10.1016/j.atherosclerosis.2009.08.018. Epub 2009 Aug 19.
3
Impact of plasma tissue inhibitor of metalloproteinase-1 on long-term survival in patients with gastric cancer.
中国南方人群中功能性-1562C>T多态性、基质金属蛋白酶-9血清水平与肾结石风险
Front Med (Lausanne). 2023 Jun 2;10:1175798. doi: 10.3389/fmed.2023.1175798. eCollection 2023.
4
Cytokinopathy with aberrant cytotoxic lymphocytes and profibrotic myeloid response in SARS-CoV-2 mRNA vaccine-associated myocarditis.SARS-CoV-2 mRNA 疫苗相关心肌炎中的细胞因子病伴异常细胞毒性淋巴细胞和促纤维化髓系反应。
Sci Immunol. 2023 May 12;8(83):eadh3455. doi: 10.1126/sciimmunol.adh3455. Epub 2023 May 5.
5
Harnessing the Plasma Proteome to Mirror Current and Predict Future Cardiac Remodeling After Myocardial Infarction.利用血浆蛋白质组学来反映心肌梗死后当前和预测未来的心脏重构。
J Cardiovasc Transl Res. 2023 Feb;16(1):3-16. doi: 10.1007/s12265-022-10326-w. Epub 2022 Oct 5.
6
Assessment of Atherosclerosis in Ischemic Stroke by means of Ultrasound of Extracranial/Intracranial Circulation and Serum, Urine, and Tissue Biomarkers.通过颅外/颅内循环超声以及血清、尿液和组织生物标志物评估缺血性卒中中的动脉粥样硬化
Curr Med Chem. 2023;30(10):1107-1121. doi: 10.2174/0929867329666220817123442.
7
Leukocyte subtypes, gelatinases, and their tissue inhibitors in a group of subjects with asymptomatic carotid atherosclerosis.无症状性颈动脉粥样硬化患者白细胞亚型、明胶酶及其组织抑制剂。
Clin Hemorheol Microcirc. 2022;82(1):37-51. doi: 10.3233/CH-221380.
8
Macrophages secrete murinoglobulin-1 and galectin-3 to regulate neutrophil degranulation after myocardial infarction.巨噬细胞分泌鼠球蛋白-1 和半乳糖凝集素-3 以调节心肌梗死后中性粒细胞脱颗粒。
Mol Omics. 2022 Mar 28;18(3):186-195. doi: 10.1039/d1mo00519g.
9
Pathophysiology of Circulating Biomarkers and Relationship With Vascular Aging: A Review of the Literature From VascAgeNet Group on Circulating Biomarkers, European Cooperation in Science and Technology Action 18216.循环生物标志物的病理生理学及其与血管衰老的关系:来自VascAgeNet循环生物标志物小组、欧洲科技合作行动18216的文献综述
Front Physiol. 2021 Dec 14;12:789690. doi: 10.3389/fphys.2021.789690. eCollection 2021.
10
PY receptor blockers are anti-inflammatory drugs inhibiting both circulating monocytes and macrophages including THP-1 cells.PY 受体阻滞剂是一种抗炎药物,可抑制循环单核细胞和巨噬细胞,包括 THP-1 细胞。
Sci Rep. 2021 Aug 31;11(1):17459. doi: 10.1038/s41598-021-95710-3.
血浆金属蛋白酶组织抑制因子-1对胃癌患者长期生存的影响。
Gastric Cancer. 2009;12(1):31-6. doi: 10.1007/s10120-008-0494-3. Epub 2009 Apr 24.
4
Relations of serum MMP-9 and TIMP-1 levels to left ventricular measures and cardiovascular risk factors: a population-based study.血清基质金属蛋白酶-9和金属蛋白酶组织抑制因子-1水平与左心室指标及心血管危险因素的关系:一项基于人群的研究。
Eur J Cardiovasc Prev Rehabil. 2009 Jun;16(3):297-303. doi: 10.1097/HJR.0b013e3283213108.
5
Tissue inhibitor of metalloproteinases levels in patients with chronic heart failure: an independent predictor of mortality.慢性心力衰竭患者金属蛋白酶组织抑制剂水平:死亡率的独立预测指标
Eur J Heart Fail. 2008 Apr;10(4):388-95. doi: 10.1016/j.ejheart.2008.02.015. Epub 2008 Mar 17.
6
Circulating matrix metalloproteinase-9 is associated with cardiovascular risk factors in a middle-aged normal population.循环中的基质金属蛋白酶-9与中年正常人群的心血管危险因素相关。
PLoS One. 2008 Mar 12;3(3):e1774. doi: 10.1371/journal.pone.0001774.
7
The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID study.在血脂干预和缺血性心脏病试验(LIPID研究)中,脑钠肽N端片段和基质金属蛋白酶-1组织抑制剂水平作为心血管结局预测指标的价值。
Eur Heart J. 2008 Apr;29(7):923-31. doi: 10.1093/eurheartj/ehn007. Epub 2008 Feb 22.
8
MMP inhibitors in cardiac diseases: an update.心脏病中的基质金属蛋白酶抑制剂:最新进展
Recent Pat Cardiovasc Drug Discov. 2007 Nov;2(3):186-94. doi: 10.2174/157489007782418964.
9
Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer.基质金属蛋白酶-9(MMP-9)和金属蛋白酶组织抑制因子-1(TIMP-1)在乳腺癌血清及组织中的表达及其预后意义
Int J Cancer. 2008 May 1;122(9):2050-6. doi: 10.1002/ijc.23337.
10
Impact of plasma tissue inhibitor of matrix metalloproteinase-1 on long-term survival in patients with colorectal cancer.血浆基质金属蛋白酶-1组织抑制剂对结直肠癌患者长期生存的影响。
Oncology. 2007;72(3-4):205-8. doi: 10.1159/000112827. Epub 2007 Dec 21.